An Overview of Key Psychosis Statistics

Roughly 23 million people worldwide live with schizophrenia alone, and psychotic experiences extend well beyond that single diagnosis. The numbers behind psychosis span prevalence, risk factors, treatment response, economic costs, and social outcomes, and they collectively paint a picture of a condition that is both more common and more consequential than many people realize. Some of these statistics are encouraging, particularly around early treatment, while others reveal persistent gaps in care and life expectancy that have barely narrowed in decades.

How Common Psychosis Is Globally

Schizophrenia is the most studied psychotic disorder, and global tracking through the Global Burden of Disease project gives us a clear view of its trajectory. In 2021, about 23.2 million people worldwide were living with schizophrenia, which works out to roughly 0.3% of the global population. The age-standardized prevalence rate was about 278 per 100,000 people.¹ That number has been climbing steadily: between 1990 and 2021, the total number of people with schizophrenia grew from about 13.6 million to 23.2 million, an increase of over 70%. New cases per year rose from 883,000 to over 1.2 million during the same period.²

Those figures cover only schizophrenia. Psychosis itself is broader, encompassing schizoaffective disorder, brief psychotic episodes, substance-induced psychosis, bipolar psychosis, and psychotic features in severe depression. Lifetime prevalence of any psychotic experience, including transient or subclinical ones, runs considerably higher than the schizophrenia-specific figure. The 0.3% number, then, represents the floor rather than the ceiling for how often psychosis appears in a population.

Gender Differences in Onset and Outcomes

Schizophrenia and first-episode psychosis do not land equally on men and women. Multiple studies have found that incidence is higher in men, and that men tend to develop symptoms earlier.³ On average, women reach the threshold for a first psychotic episode about a year later than men.⁴

That gap in age of onset has downstream effects. A ten-year follow-up of first-episode psychosis patients found that women were older at admission and at illness onset (around 31 versus 27 years), had higher premorbid functioning throughout childhood and adulthood, had higher premorbid IQ and education levels, and were more likely to be living independently, employed, and in a relationship at the time of their first episode.⁵ In practical terms, women often have more social and functional scaffolding in place before illness strikes, which can buffer outcomes. This has led researchers to argue that treatment strategies should be tailored by gender rather than treating psychosis as a one-size-fits-all condition.

The Genetics Behind Psychosis Risk

Psychotic disorders run in families, and twin studies make the genetic contribution hard to ignore. A nationwide Danish twin registry study estimated the heritability of schizophrenia at about 79%, with the concordance rate in identical twins at 33% compared to 7% in fraternal twins. When the definition was expanded to include the broader schizophrenia spectrum, heritability stayed in a similar range at about 73%.⁶

But heritability is not destiny. The fact that identical twins share the same DNA yet only one-third of co-twins develop schizophrenia when the other has it tells you that environment matters enormously. The genetic architecture itself is complex: schizophrenia is a polygenic condition, meaning it involves likely more than 100 genes, each contributing a small amount of risk. Genome-wide association studies have identified specific risk locations across the genome, but collectively the identified variants explain only a fraction of the overall genetic liability.⁷ There is no single “schizophrenia gene” to test for, and the heritability estimates describe population-level patterns, not individual predictions.

Environmental Risk Factors

Several environmental exposures have emerged as consistent risk factors for psychosis, and they tend to cluster together in ways that make isolating any single cause difficult.

Urban living is one of the most replicated findings. People born or raised in cities have higher rates of schizophrenia and psychotic experiences compared to those from rural areas. A 2024 review examined 43 studies on the relationship between urbanization and psychosis-related outcomes and confirmed the association.⁸ Earlier research had already established that urbanicity is linked to higher incidence of schizophrenia and non-affective psychosis specifically.⁹ The reasons likely involve a combination of social fragmentation, pollution, noise, crowding, and the experience of inequality, though the exact mechanisms remain debated.

Cannabis use is another well-documented risk factor. Longitudinal studies have found that regular cannabis use predicts a higher risk of developing schizophrenia and of reporting psychotic symptoms, even after controlling for other drug use and personal characteristics. The relationship does not appear to be explained by people using cannabis to self-medicate pre-existing symptoms, and it has biological plausibility because the cannabinoid system interacts directly with dopamine pathways involved in psychosis.¹⁰

Childhood adversity stands out as a particularly powerful predictor. A dose-response meta-analysis found that the risk of psychosis climbs with each additional adverse experience in childhood. Compared to people with no childhood adversity, those with a single exposure had roughly 1.8 times the risk. At five or more exposures, the odds ratio jumped to about 6.5, a steep and consistent gradient.¹¹ The relationship was nonlinear, meaning risk accelerated with accumulating trauma rather than increasing at a steady rate.

Migration, Ethnicity, and Social Disadvantage

One of the more striking findings in psychosis epidemiology is that certain ethnic minority groups in Western countries develop psychotic disorders at rates far higher than the majority population. Meta-analytic evidence has confirmed elevated incidence rates among both first- and second-generation immigrants, with substantial variation depending on the specific ethnic group and the host country context.¹² In some minority groups, psychotic disorders are up to five times more common than in the white majority.¹³

These disparities persist even in rural areas, ruling out urbanicity as the sole explanation. A UK study found that people of Black African origin had about four times the risk of first-episode psychosis compared to the white British population, and people of Black Caribbean origin had roughly 4.6 times the risk, even after adjusting for multiple other variables.¹⁴ These numbers do not reflect genetic vulnerability in particular ethnic groups. Rather, the prevailing explanation centers on the chronic stress of social disadvantage, discrimination, reduced social capital, and the experience of being a visible minority, all of which converge to elevate psychosis risk.

Why Getting Treatment Early Matters So Much

One of the most actionable statistics in psychosis research involves the duration of untreated psychosis, or DUP: the gap between when psychotic symptoms first appear and when treatment begins. This interval predicts outcomes across nearly every domain that matters. A large umbrella review and meta-analysis found that a longer DUP at first presentation was associated with more severe negative symptoms and a higher chance of previous self-harm. At follow-up, longer DUP was linked to more severe positive symptoms, more severe negative symptoms, poorer overall functioning, and a significantly lower chance of achieving remission.¹⁵ The effect sizes were clinically meaningful: a DUP of four weeks predicted over 20% more severe symptoms at follow-up compared to a DUP of just one week.

These findings have been corroborated in individual studies. A systematic review of first-episode cohorts found a consistent association between DUP and outcomes at both six and twelve months, including total symptoms, functioning, and quality of life, and patients with a long DUP were less likely to achieve remission.¹⁶ In drug-naïve patients specifically, those with a shorter DUP showed better negative symptom scores from week four onward, better global functioning, required lower medication doses by week twelve, and were significantly more likely to reach a meaningful reduction in symptoms. The gap between the short-DUP and long-DUP groups widened over time, suggesting that treatment delays allow symptoms to become entrenched.¹⁷

Clinical High Risk and Transition to Full Psychosis

Not everyone who shows early warning signs of psychosis goes on to develop a full psychotic disorder, but the risk is not trivial. Among people identified as being at clinical high risk, a meta-analysis found that about 15% transitioned to psychosis within one year, about 20% within two years, and about 25-28% by three to four years.¹⁸ An earlier meta-analysis reported a somewhat higher overall transition rate of about 29% at a mean follow-up of roughly two and a half years, with risk continuing to climb out to three years and beyond.¹⁹

These numbers carry two implications. First, a clinical high-risk state is a genuine warning signal, not just a false alarm. Second, the majority of people identified as high-risk do not convert to psychosis, which means that early intervention services face the challenge of helping a mixed group where some individuals are on a trajectory toward illness and others are not. Getting the balance right between acting early enough to matter and avoiding unnecessary treatment in people who would have recovered anyway is an ongoing tension in the field.

The Life Expectancy Gap

People with schizophrenia die 15 to 20 years earlier than the general population. This is one of the most consistently replicated findings in psychiatric epidemiology, and the gap has not meaningfully closed despite decades of awareness.²⁰ A study following over 600 patients with schizophrenia for ten years found the mean age at death was about 59, compared to a general population life expectancy in the same country of about 76, a gap of roughly 17 years. The standardized mortality ratio was 1.58, meaning the death rate was 58% higher than expected.²¹

Suicide and accidents account for a meaningful share of excess deaths, but the largest portion comes from preventable physical causes: cardiovascular disease, infections, respiratory illness, and cancer.²⁰ Life expectancy in people with schizophrenia has been rising in high-income countries, broadly tracking the general population’s improvements, but excess mortality remains stubbornly high, with no realistic prospect of reaching general population levels in the near term.²² Metabolic syndrome and cardiovascular risk factors are highly prevalent in this population, driven by both the illness itself and the metabolic side effects of antipsychotic medications.²³

Suicide Risk

The lifetime suicide rate in people with schizophrenia is estimated at around 5% to 13%, with the higher end of that range considered the more accurate figure.²⁴ Some estimates place the figure at approximately 10%.²⁵ To put that in context, the lifetime risk of suicide in the general population is below 2% even in higher-risk countries. Suicide risk is highest in the early years after diagnosis, particularly around the first episode, which adds urgency to early intervention efforts.

Substance Use Comorbidity and Treatment Adherence

Substance use is remarkably common alongside psychosis. Estimates suggest that as many as half of people with schizophrenia have a co-occurring drug or alcohol disorder.²⁶ This comorbidity complicates nearly every aspect of care, from initial diagnosis through long-term management, and is one of the strongest predictors of medication nonadherence.

Adherence to antipsychotic medication itself is a major challenge. A study of first-episode psychosis patients found that at four-year follow-up, about 24% were nonadherent to medication. Nonadherence was associated with substance misuse, more severe symptoms, less insight into the illness, lower overall functioning, and negative attitudes toward medication. Those who were nonadherent had more hospital readmissions.²⁷ Antipsychotic treatment makes a measurable difference in preventing relapse: in people who experienced cannabis-induced psychosis, for instance, any antipsychotic use was associated with a 25% lower risk of subsequent psychosis hospitalization.²⁸

Treatment-Resistant Schizophrenia and Clozapine

About 25% to 33% of people with schizophrenia do not respond adequately to standard antipsychotic medications, a category known as treatment-resistant schizophrenia. Clozapine is the only antipsychotic with demonstrated superiority for this group, but its effectiveness is far from universal. A systematic review and meta-analysis found that about 40% of treatment-resistant patients responded to clozapine, with a clinically meaningful average reduction in symptoms of about 26% from baseline.²⁹ That 40% response rate implies that roughly 12% to 20% of all people with schizophrenia are “ultra-resistant,” meaning they do not respond even to the most effective available medication.

A more recent retrospective study reported a higher response rate of 54% at twelve weeks, with 94% of those responders maintaining their improvement at one year. Among those who initially did not respond, about a third showed improvement by the one-year mark, suggesting that clozapine sometimes takes longer to work than the typical trial period allows.³⁰ These numbers highlight both the promise and the limitation of current treatment: clozapine genuinely helps a large proportion of people who have failed other medications, but a meaningful minority remains without an effective pharmacological option.

The Economic Weight of Psychosis

The financial burden of schizophrenia is enormous and extends far beyond direct healthcare spending. In the United States, the total societal cost of schizophrenia in 2024 was estimated at about $367 billion. Direct costs, including healthcare, supportive housing, homelessness-related expenses, justice system interactions, and disability benefits, totaled about $75 billion. But indirect costs dwarfed them at roughly $292 billion, including lost wages for patients, reduced quality of life and life expectancy, and the substantial burden on unpaid family caregivers, whose lost wages and health impacts alone accounted for over $165 billion.³¹

This pattern, where indirect costs dominate, holds globally. A systematic review across multiple countries found that indirect costs accounted for 50% to 85% of total schizophrenia-related spending, and the total economic burden ranged from 0.02% to 1.65% of a country’s GDP.³² Per-person annual costs varied enormously across ten countries, from about $2,000 to over $94,000, but in every setting indirect costs were the dominant driver.³³ The message here is that the true cost of schizophrenia is not primarily in pills and hospital beds. It is in lost human potential and in the ripple effects on families.

Employment and Social Outcomes

Employment rates among people with schizophrenia are strikingly low, though they vary widely by country and measurement method, ranging from as low as 4% to about 50% across different studies.³⁴ A Scandinavian population study captured the trajectory: about 24% of people with schizophrenia were employed three years before their first diagnosis, but that rate fell to just 10% five years after diagnosis. For comparison, people with bipolar disorder started at 45% employment and dropped to 34% over the same timeframe.³⁵

The social consequences extend beyond employment. In a large U.S. Veterans Health Administration study, veterans with schizophrenia were roughly five times more likely to be unemployed and four and a half times more likely to experience homelessness compared to veterans without the disorder. Rates of divorce and incarceration were also elevated.³⁶ These downstream social failures are both a consequence of the illness and, through the stress and instability they create, a factor that worsens its course.

Victimization Versus Violence

Public perception tends to link psychosis with violence perpetration, but the data tell a different story. A systematic review and meta-analysis found that people with psychotic disorders are more often victims of violence than perpetrators.³⁷ Among psychiatric outpatients, 20% to 34% had been violently victimized in the past one to three years, compared to 2% to 13% who had perpetrated violence. When both outpatients and inpatients were combined, about 35% had been victims in the past year, versus 12% to 22% who had been perpetrators.³⁸

In a study of over 1,100 people with schizophrenia, about 17.5% reported being victimized over an 18-month period. Among those who were victimized, a little over half had also engaged in violent behavior themselves, suggesting that victimization and perpetration can overlap in the same individuals rather than cleanly separating people into “dangerous” and “vulnerable” categories.³⁹ The overall takeaway is that the public health concern around psychosis and violence is real, but it is primarily a concern about people with psychosis being harmed, not about them harming others. Media portrayals that emphasize danger to the public are not supported by the weight of the evidence and contribute to stigma that makes it harder for people to seek help.

Postpartum Psychosis

Postpartum psychosis is rare but severe. It typically emerges in the first days to weeks after childbirth and is considered a psychiatric emergency because of the speed of onset and the potential risk to both the parent and infant. The condition is not classified as a standalone diagnosis in major diagnostic systems, which means it is grouped with other psychotic episodes in clinical coding. This lack of a distinct classification can make epidemiological tracking more difficult and may contribute to underrecognition. Women with a prior history of bipolar disorder or psychosis face the highest risk, though postpartum psychosis can also appear in women with no prior psychiatric history. Estimates from epidemiological studies generally place the incidence at roughly one to two per thousand deliveries, making it uncommon but not vanishingly so in the context of millions of births per year worldwide.